source
- Otsuka's Voyxact reduces kidney function decline in IgA nephropathy but falls short of expectations in Phase 3Otsuka reported Phase 3 trial results for its drug Voyxact in patients with IgA nephropathy, a chronic autoimmune kidney disease. In the study, patients receiving Voyxact experienced an annualized…
- Acting FDA Commissioner Kyle Diamantas says he will not seek permanent appointmentActing FDA Commissioner Kyle Diamantas has indicated that he does not intend to remain in the role on a permanent basis. Sources close to the administration say that the search for a new permanent…